See nothing in the program HPV related,yet...but there remain several open presentation slots and abstracts just closed.
Timing seems coordinated with October treatment guideline statement.Was rather surprised to see nothing on the schedule wrt HPV.
donmar remember that there will be close to 190mm shares out of qgen once merger fully done...but yeah, rapid hpv growth can only help
more on options in case anyone still has in the money calls since we still don't know what the consideration will be for non-elected shares
if you have calls they are now considered non-standard so they can't be exercised online for example, you have to call and have a broker submit the exercise
once you exercise you don't know what you'll get until qiagen finishes the back end merger which could be this week but maybe not
once you exercise the go into a queue at the OCC and you'll get stock, stock/cash, or all cash (the last being most likely imho) once it's determined
if you don't exercise them prior to expiration friday for the septs then you will get zip, nada, nothing
that's my current understanding in any case, just thought i'd pass it along
Comparison of the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 Assay for detection of high-risk human papillomavirus in women with abnormal PAP smear.
De Francesco MA, Gargiulo F, Schreiber C, Ciravolo G, Salinaro F, Manca N.
Institute of Microbiology and Virology, Spedali Civili, University of Brescia, Brescia, Italy.
Infection with human papillomavirus (HPV) is a necessary step in the progression to cervical cancer. Many methods for HPV testing are currently available, mostly developed to detect pools of HPV types. Hybrid Capture 2 (HC2) is one of the most widely used. A new PCR-based assay, the Roche AMPLICOR HPV test, has been recently developed. Both assays recognize a group of 13 HR HPV types contemporaneously. This study evaluated the performance of both methods for detecting high-grade cervical lesions as a part of management for abnormal PAP smears. The study population was composed of 213 women, all referred to colposcopy and histologic diagnosis following an abnormal PAP test. Biopsy-confirmed high-grade cervical intraepithelial neoplasia was used as a gold standard. Overall agreement was 84.9% with a kappa value of 0.6. When comparing the ability to detect moderate cervical intraepithelial neoplasia (CIN2+) and high-grade cervical intraepithelial neoplasia (CIN3+/cancer), AMPLICOR proved slightly more sensitive than HC2, a finding that is important when HPV testing is used in a triage of borderline smear results. Genotyping of discordant results showed a prevalence of LR-HPV types in HC2 positive/AMPLICOR negative samples, and a similar prevalence of HR- and LR-HPV types in AMPLICOR positive/HC2 negative samples. In conclusion, the study shows that the AMPLICOR assay is more sensitive than HC2, which makes it a valid alternative for routine clinical use.
PMID: 17854914 [PubMed - as supplied by publisher
Also toss in several millions of tests a year outside the US (and net margins I think are still above $10 per test) and you can arrive at a larger profit per share increase with what we hope will show up in the share price.
Still very bizzare to me but guess it is how the medical system works is that QGEN gets a profit of $10-$20 per test, the test is covered by nearly all insurance, yet if a woman has to self pay for the test it costs her between $200 and $300 to add the test in addition to cost of cytology and office visit. Go figure...
Anyone know when the latest round of shares vs. cash election will show up in the account?
Sure is less excitement watching/trading QGEN compared to DIGE. Guess I should be happy but just more bored.
Next month will be better when I can show the local docs the new guidelines and perhaps convert a few.
30 million tests per year times $10 profit per test divided by 150 million QGEN shares equals $2 per share profit , so could be $40 per share increase based on HPV test ? Change a number, change the result, but seems like it could be good if SOC becomes real...and QGEN doesn't have all that "I'll get mine " only attitude.
gotta say that it's tough finally reaching the threshold of an hpv explosion and DIGE is no longer ... just wonder what impact it will have on QGEN sp? 30 cents? 10/1 on in DIGE could have been a pretty exciting time
you can download the program but it is a large PDF file...check this course out by two of our biggest fans, Mark "only use an FDA approved test" Stoler, and Tom "Former Digene Pet Doc" Wright
<<SP43 AP/CYTO Symposium: Cervical Neoplasia Screening
and Management in the HPV Era: Updated Guidelines
from the ASCCP - NEW
Mark H. Stoler, MD, FASCP, University of Virginia Health Sciences
Center, Charlottesville, VA
Thomas C. Wright, MD, FASCP, Columbia University, College of
Physicians and Surgeons, New York, NY
The conventional Pap smear is the world�s most
successful cancer screening test yet clearly molecular
testing for HPV has dramatically changed clinical
practice and continues to evolve. In 2006, The
American Society of Colposcopy and Cervical
Pathology�s (ASCCP) held a second broad-based
consensus conference to refine and update their highly
successful guidelines for the clinical management of
women with cervical neoplasia. The outcomes of these
wide-ranging discussions directly impact all who
practice in this area, and HPV testing is even more
integral to virtually all management pathways. It is
essential that pathologists understand the new
guidelines and the data supporting their use.
Hear first-hand from Drs. Stoler and Wright as they
present cases and discussions of:
� The molecular basis of HPV testing
� A definition of the basis for what is and is not
a good HPV test
� The impact of HPV testing on screening
� Why HPV testing should be the standard of care
� The interplay between HPV testing and management
of both cytology and histology using the revised
Attendees will be encouraged to ask questions and
join the discussion.
Following this course, you will be able to:
� Interpret the diagnostic and clinical applications
of the major findings from the ALTS trial and other
HPV testing trials.
� Apply these data in the management of cytologic
and histologic interpretations as specified in the
new ASCCP guidelines.
� Understand the clinical and medico-legal implication
of the interaction between HPV testing and cervical
cytology as they impact the contemporary practice
Saturday, October 20
HEME SURG CYTO MOC MK PC PBL MOC PC PBL>>
Also there is a good page on the new digene site that lists upcoming meetings where they have a booth...haven't looked at all of them but bet ASCCP 2006 will be a big topic in most
for instance NPWH already endorsed DWP earlier this year based on their participation in the Consensus meeting